Ocular adverse event profiles associated with endocrine therapies for breast cancer: a global pharmacovigilance study using FAERS and VigiAccess
Ocular adverse events may affect tolerability during long-term endocrine therapy for breast cancer, but comparative real-world evidence remains limited. We characterized ocular adverse-event reporting patterns using the FDA Adverse Event Reporting System (FAERS) and VigiAccess. FAERS reports from Q1–2004 to...